PMID- 32316657
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20210122
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 25
IP  - 8
DP  - 2020 Apr 17
TI  - Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored 
      Therapies in Solid Tumors.
LID - 10.3390/molecules25081864 [doi]
LID - 1864
AB  - Fluorescence in situ hybridization (FISH) is a standard technique used in routine 
      diagnostics of genetic aberrations. Thanks to simple FISH procedure is possible 
      to recognize tumor-specific abnormality. Its applications are limited to designed 
      probe type. Gene rearrangements e.g., ALK, ROS1 reflecting numerous 
      translocational partners, deletions of critical regions e.g., 1p and 19q, gene 
      fusions e.g., COL1A1-PDGFB, genomic imbalances e.g., 6p, 6q, 11q and 
      amplifications e.g., HER2 are targets in personalized oncology. Confirmation of 
      genetic marker is frequently a direct indication to start specific, targeted 
      treatment. In other cases, detected aberration helps pathologists to better 
      distinguish soft tissue sarcomas, or to state a final diagnosis. Our main goal is 
      to show that applying FISH to formalin-fixed paraffin-embedded tissue sample 
      (FFPE) enables assessing genomic status in the population of cells deriving from 
      a primary tumor or metastasis. Although many more sophisticated techniques are 
      available, like Real-Time PCR or new generation sequencing, FISH remains a 
      commonly used method in many genetic laboratories.
FAU - Chrzanowska, Natalia Magdalena
AU  - Chrzanowska NM
AD  - Molecular Oncology and Genetics Department, Innovative Medical Forum, The F. 
      Lukaszczyk Oncology Center, 85-796 Bydgoszcz, Poland.
FAU - Kowalewski, Janusz
AU  - Kowalewski J
AD  - Department of Thoracic Surgery and Tumors, Ludwik Rydygier Collegium Medicum in 
      Bydgoszcz, Nicolaus Copernicus University, 85-067 Torun, Poland.
FAU - Lewandowska, Marzena Anna
AU  - Lewandowska MA
AUID- ORCID: 0000-0002-7360-7810
AD  - Molecular Oncology and Genetics Department, Innovative Medical Forum, The F. 
      Lukaszczyk Oncology Center, 85-796 Bydgoszcz, Poland.
AD  - Department of Thoracic Surgery and Tumors, Ludwik Rydygier Collegium Medicum in 
      Bydgoszcz, Nicolaus Copernicus University, 85-067 Torun, Poland.
LA  - eng
GR  - UMK CM 2018 WL103/Uniwersytet Mikolaja Kopernika w Toruniu/
PT  - Journal Article
PT  - Review
DEP - 20200417
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Molecular Probes)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - Chromosome Painting
MH  - Humans
MH  - Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence/methods
MH  - Molecular Probes
MH  - Neoplasms/*diagnosis/genetics/metabolism/therapy
MH  - Precision Medicine
MH  - Reproducibility of Results
PMC - PMC7221545
OTO - NOTNLM
OT  - ALK
OT  - COL1A1-PDGFB
OT  - FISH
OT  - HER2
OT  - ROS1
OT  - personalized medicine
OT  - personalized oncology
OT  - t(X,18)
OT  - targeted treatment
COIS- The authors declare no conflict of interest.
EDAT- 2020/04/23 06:00
MHDA- 2021/01/23 06:00
PMCR- 2020/04/17
CRDT- 2020/04/23 06:00
PHST- 2020/03/09 00:00 [received]
PHST- 2020/04/05 00:00 [revised]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
PHST- 2020/04/17 00:00 [pmc-release]
AID - molecules25081864 [pii]
AID - molecules-25-01864 [pii]
AID - 10.3390/molecules25081864 [doi]
PST - epublish
SO  - Molecules. 2020 Apr 17;25(8):1864. doi: 10.3390/molecules25081864.